J Korean Diabetes.  2023 Sep;24(3):107-110. 10.4093/jkd.2023.24.3.107.

Approach to Fatty Liver Disease in Patients with Type 2 Diabetes

• Bae JC

• KMID: 2546626
• DOI: http://doi.org/10.4093/jkd.2023.24.3.107

Abstract

Type 2 diabetes is a major risk factor for development and progression of non-alcoholic fatty liver disease (NAFLD). Fatty liver is prevalent in people with type 2 diabetes, and overweight or obesity in these patients aggravates insulin resistance and steatohepatitis, which appear to be drivers for the disease progression. The goal of screening is not to identify steatosis itself, but rather to identify patients at risk for adverse hepatic outcomes such as cirrhosis, hepatocellular carcinoma, and death from liver disease. The most important risk factors for disease progression are liver fibrosis and its severity. There is a consensus that the FIB-4 (fibrosis-4 index) is the most cost-effective strategy for initial screening of hepatic fibrosis in a clinical setting. At present, there are no approved drugs for the treatment of NAFLD. Clinically significant improvements in NAFLD are achieved with weight loss. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors are effective for inducing weight loss in patients with type 2 diabetes, and some GLP-1 RAs and SGLT2 inhibitors have been shown to be effective for treating steatohepatitis. Therefore, GLP-1 RAs and SGLT2 inhibitors should be considered when choosing antidiabetic agents in patients with type 2 diabetes and NAFLD, especially in those who are overweight or obese.

Keyword

Diabetes mellitus; Fatty liver; Fibrosis

Reference

1.Younossi ZM. Nonalcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019. 70:531–44.

2.Han E., Han KD., Lee YH., Kim KS., Hong S., Park JH, et al. Fatty liver & diabetes statistics in Korea: nationwide data 2009 to 2017. Diabetes Metab J. 2023. 47:347–55.

3.Kang SH., Lee HW., Yoo JJ., Cho Y., Kim SU., Lee TH, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021. 27:363–401.

4.Ando Y., Jou JH. Nonalcoholic fatty liver disease and re-cent guideline updates. Clin Liver Dis (Hoboken). 2021. 17:23–8.

5.Barb D., Repetto EM., Stokes ME., Shankar SS., Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring). 2021. 29:1950–60.

6.Angulo P., Kleiner DE., Dam-Larsen S., Adams LA., Bjorns-son ES., Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015. 149:389–97.e10.

7.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D, et al. 4. Comprehensive medical evalu-ation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S49–67.

8.Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001. 34(4 Pt 1):738–44.

9.Cusi K., Isaacs S., Barb D., Basu R., Caprio S., Garvey WT, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and en-docrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022. 28:528–62.

10.Castera L., Friedrich-Rust M., Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019. 156:1264–81.e4.

11.Eddowes PJ., Sasso M., Allison M., Tsochatzis E., Anstee QM., Sheridan D, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019. 156:1717–30.

12.Nevola R., Epifani R., Imbriani S., Tortorella G., Aprea C., Galiero R, et al. GLP-1 receptor agonists in nonalcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023. 24:1703.

13.Androutsakos T., Nasiri-Ansari N., Bakasis AD., Kyrou I., Efstathopoulos E., Randeva HS, et al. SGLT2 inhibitors in NAFLD: expanding their role beyond diabetes and cardi-oprotection. Int J Mol Sci. 2022. 23:3107.

14.Musso G., Cassader M., Paschetta E., Gambino R. Thi-azolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017. 177:633–40.